Answers are grounded in this paper and cite their sources.
Analysis establishes normal MHR ranges and its association with inflammation and mortality across diseases, implying predictive value for clinical outcomes.
Traditional inflammatory biomarkers fail to capture the interplay between inflammation and lipid metabolism, key drivers of disease progression, especially in the context of cardiovascular-kidney-metabolic health [1]. The novel Monocyte-to-HDL Ratio (MHR) biomarker reflects monocyte-driven inflammation and HDL’s anti-inflammatory properties [2]. MHR's reference ranges and prognostic utility remain undefined. This study establishes normal MHR reference ranges and examines its association with various inflammatory diseases and associated mortality, including cardiovascular diseases (CVD), respiratory diseases (RD), kidney diseases (KD), diabetes mellitus (DM), and cancers.
No takes yet. Share an insight, caveat, or question.
Arabi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: